Effect observation of telbivudine in the treatment of HBeAg-positive chronic hepatitis B

Objective To observe the effect of telbivudine in the treatment of HBeAg -positive chronic hepatitis B. Methods Clinical data of 104 patients with HBeAg-positive chronic hepatitis B treated in infectious disease department of the 6th people's hospital of Shenyang City from February 2010 to February 2012 were analyzed retrospectively. 52 patients treated with telbivudine were selected as the telbivudine group, 52 patients treated with lamivudine were selected as the lamivudine group. 12, 24, 52 weeks after treatment, the serum ALT normalization rate, HBV DNA negative rate and HBeAg serological conversion rate of the two groups were observed and compared. Results Twelve weeks after treatment, the serum ALT normalization rates, HBV DNA negative rates and HBeAg serological conversion rates between the telbivudine group and the lamivudine group had no significant differences (P 0.05). 24 weeks after treatment, the HBeAg serological conversion rates in telbivudine group (13.5%) was highter than the lamivudine group (5.8%), had significant differences (P 0.05). 52 weeks after treatment, the serum ALT normalization rate, HBV DNA negative rate and HBeAg serological conversion rate in the telbivudine group were all significantly higher than those in the lamivudine group (P 0.05). Conclusion The effect of telbivudine in the treatment of HBeAg-positive chronic hepatitis B is better, which is also a safety method for treatment, it is worthy of clinical application.